Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
Gyre Therapeutics, Inc. (GYRE)
Company Research
Source: GlobeNewswire
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the appointment of Rodney L. Nussbaum to the Company’s Board of Directors and as a member of its Audit Committee. “Rodney has an extensive background in finance, accounting, and financial reporting with nearly four decades of experience working at global auditing and consulting firms,” said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. “He joins our Board at a pivotal time as we advance our diversified pipeline of anti-fibrotic therapies. We look forward to leveraging his expertise to help drive Gyre’s commercial growth.” “I am thrilled to have the opportunity to join the Gyre Board of Directors at such an exciting time for the Company,” said Mr. Nussbaum. “I look forward to using my experience to support Gyre’s multi-faceted strategy of inc
Show less
Read more
Impact Snapshot
Event Time:
GYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GYRE alerts
High impacting Gyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GYRE
News
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Public companies are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) biggest owners and were rewarded after market cap rose by US$137m last week [Yahoo! Finance]Yahoo! Finance
- Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time [Seeking Alpha]Seeking Alpha
- Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
GYRE
Sec Filings
- 5/9/24 - Form 8-K
- 5/8/24 - Form 8-K
- 5/2/24 - Form 4
- GYRE's page on the SEC website